{"title":"PARP inhibitors in metastatic prostate cancer: current evidence and future directions.","authors":"Kate McKendry, Corinne Maurice-Dror, Kim N Chi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Inhibitors of poly(ADP-ribose) polymerase (PARPis) are an established treatment for homologous recombination repair gene-altered metastatic prostate cancer. The efficacy of PARPis-both as single agents and in combination with androgen receptor pathway inhibitors (ARPIs)-was first established in patients with metastatic castration-resistant prostate cancer (mCRPC, more recently termed androgen pathway modulation-resistant [APMR] prostate cancer), with the greatest benefit observed in BRCA2-altered disease. This review focuses on the more recently demonstrated evidence of the benefit of PARPis in combination with standard-of-care ARPIs and androgen deprivation therapy for patients with metastatic hormone-sensitive prostate cancer (mHSPC, also termed androgen pathway modulation-sensitive [APMS] prostate cancer) generated by the AMPLITUDE and TALAPRO-3 trials, which evaluated niraparib and talazoparib, respectively. How broadly PARPis will be incorporated into the clinical management of patients with mHSPC/APMS will depend on the perception of issues such as optimal patient eligibility (including biomarker selection), short- and long-term treatment-related adverse events, other available treatment options, and treatment sequencing. The review also examines future directions for PARPi therapy for the mHSPC/APMS disease state, including the ongoing EvoPAR-Prostate01 phase 3 registration trial evaluating the PARP1-selective agent saruparib.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 8","pages":"487-498"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149381812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"How I treat MDS/AML: individualizing therapy based on disease biology, patient fitness, molecular features, and treatment goals.","authors":"Courtney D DiNardo","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 8 Suppl 12","pages":"1-12"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149381813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"From ADAURA to LAURA: the evolving role of EGFR-targeted therapy in NSCLC.","authors":"Kelsey Pan, Suresh S Ramalingam","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Epidermal growth factor receptor gene (EGFR) mutations, most commonly involving exon 19 deletion or leucine-858-to-arginine substitution (L858R), define a biologically distinct subset of non-small cell lung cancers (NSCLCs). Third-generation EGFR tyrosine kinase inhibitors have transformed outcomes in metastatic disease, and this benefit has since been extended into localized and locally advanced NSCLC through 3 landmark randomized trials: ADAURA, which established adjuvant osimertinib as standard of care after the resection of stage IB-IIIA disease; NeoADAURA, which demonstrated improved pathologic responses with neoadjuvant osimertinib in resectable stage II-IIIB disease; and LAURA, which established osimertinib consolidation after chemoradiation in unresectable stage III disease. Together, these trials mark a shift away from the mutation-agnostic treatment paradigms that previously guided the treatment of earlier stages of NSCLC toward targeted therapy across curative-intent settings. This review summarizes the evidence supporting perioperative and consolidation EGFR tyrosine kinase inhibitor therapy in resectable and unresectable locally advanced EGFR-mutant NSCLC, and it addresses practical considerations including treatment sequencing, the management of radiation-related toxicity, and central nervous system surveillance. It also examines unresolved questions, including the optimal duration of adjuvant and consolidation therapy, the role of circulating tumor DNA in guiding treatment decisions, and the management of atypical EGFR mutations, which remain outside the evidence base guiding current guidelines. As precision oncology extends further into curative-intent settings, molecular selection is becoming central to treatment planning in locally advanced NSCLC.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 8","pages":"529-535"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149381810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Therapeutic approaches in aRCC: focus on patient selection for IO-IO vs IO-TKI.","authors":"Wenxin Xu","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 8 Suppl 13","pages":"1-12"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149381814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Approval versus coverage: the differences between FDA and CMS standards.","authors":"David Hyman","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 8","pages":"511-513"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149381809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Lessons and limitations of the PARADIGM trial in acute myeloid leukemia.","authors":"Hagop M Kantarjian","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 8","pages":"514-516"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149381811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"PNH management: a clinical case of ravulizumab-danicopan combination therapy.","authors":"Ilene C Weitz","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 7 Suppl 9","pages":"1-13"},"PeriodicalIF":2.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149388612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Treatment after progression and emerging sequencing strategies.","authors":"Pedro C Barata","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 7 Suppl 11","pages":"7-9"},"PeriodicalIF":2.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149388611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Precision medicine in advanced hormone receptor-positive breast cancer: integrating genomic profiling and liquid biopsy into clinical practice.","authors":"Devashish Desai, Parth Sampat, Gowthami Koorapati, Prashanth Ashok Kumar, Abirami Sivapiragasam","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Precision medicine has reshaped the management of advanced hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer by coupling treatment with tumor genomics rather than clinicopathologic features alone. In this review, we highlight the role of next-generation sequencing (NGS) in our clinical practice. We summarize the performance characteristics of various NGS platforms and outline the available techniques of NGS. We also describe clinically relevant genomic alterations and targeted treatments.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 7","pages":"465-475"},"PeriodicalIF":2.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149388604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}